{"filings":[{"id":94069,"accession_number":"0001609550-26-000026","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Inspire Medical shareholders approve declassification, 2.6M-share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved phasing out classified board; all directors to be elected annually starting 2029.","Approved amendment of 2018 Incentive Award Plan: adds 2.6M shares (total authorized 9.9M), removes evergreen, extends term to 2036.","Elected Class II directors: Ellis, Melenikiotou, Mead Jr. with >17M votes for each.","Ratified Ernst & Young as auditor (25.1M for); approved say-on-pay (22.5M for) with 1-year frequency (22.9M for).","Proposal 5 (declassification) passed with 23.1M for; Proposal 6 (equity plan) passed with 14.3M for; broker non-votes not counted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94068,"accession_number":"0001609550-26-000021","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q1 revenue up 1.6% to $204.6M; guides FY2026 revenue down 4-10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $(0.39); adjusted diluted EPS $0.10; operating cash flow $12.8M.","Coding/reimbursement uncertainty for Inspire V and WISeR program disrupted Q1.","FY2026 revenue guidance revised to $825M-$875M (decline 4-10% vs 2025).","Adjusted operating margin guidance of 2%-4%; adjusted diluted EPS $0.75-$1.25.","Expects coding challenges to persist through 2026, with growth returning in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":204583000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106174,"accession_number":"0001609550-26-000012","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","5.03","7.01","9.01"],"status":"ready","headline":"Inspire Q4 rev $269M (+12%), EPS $4.66; FY26 outlook lowered on coding change","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $269.1M (+12%); GAAP diluted EPS $4.66; adjusted EPS $1.65.","Full year revenue $912M (+14%); operating cash flow $117M; share repurchases $175M.","FY2026 revenue guidance revised to $950M-$1.0B (4-10% growth); adjusted EPS $1.85-$2.35.","Inspire V procedure coding changed to CPT 64582 with -52 modifier, reducing physician fees; company disappointed.","Board proposes declassification and removal of for-cause removal; effective upon shareholder approval at 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":4.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":911981000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106173,"accession_number":"0001609550-26-000006","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical posts preliminary Q4 rev ~$269M (+12% YoY); 2026 guidance $1,003-1,013M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 revenue ~$269M, up 12% YoY; full-year 2025 revenue ~$912M, up 14% YoY.","Initial FY 2026 revenue guidance of $1,003M-$1,013M, implying 10-11% growth over 2025.","Appointed Matt Osberg as EVP and CFO, start Jan 19, 2026; base salary $650k, sign-on $600k, equity awards $3M.","Rick Buchholz steps down as CFO, serves as interim CFO through filing of 2025 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":4.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":911981000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122455,"accession_number":"0001609550-25-000055","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Inspire Medical Systems expects $90M-$100M tax benefit from valuation allowance release","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company disclosed expectation to release a significant portion of valuation allowance on U.S. deferred tax assets.","Estimated income tax benefit of $90 million to $100 million for fiscal year 2025.","Diluted earnings per share expected to increase by approximately $3.00 to $3.30.","Disclosure made on November 6, 2025, and filed on November 17, 2025.","The benefit will be recorded in the fourth quarter of fiscal 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122454,"accession_number":"0001609550-25-000052","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q3 revenue $224.5M (+10% YoY); net income down; FY25 EPS guidance raised to $0.90-$1.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $224.5M in Q3 2025, up 10% from $203.2M a year ago; U.S. revenue $214.4M (+9%), OUS revenue $10.1M (+37%).","Gross margin 85.8% vs 84.1% YoY, driven by higher volume and Inspire V mix with lower COGS.","Net income $9.9M ($0.34 diluted EPS) vs $18.5M ($0.60) prior year; adjusted diluted EPS $0.38.","FY2025 revenue guidance reaffirmed $900M-$910M (12-13% growth); EPS guidance raised to $0.90-$1.00 from $0.40-$0.50.","Completed $50M in share repurchases; Q3 operating cash flow $68.5M; cash & investments $410.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":642904000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122453,"accession_number":"0001609550-25-000046","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire V clinical data shows superior efficacy, adherence, and reduced surgical times; AHI cut from 34.4 to 8.3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Singapore study (44 patients): Inspire V IPOP 87.1% vs Inspire IV 79.4%, exceeding non-inferiority margin of 4.6%.","Median AHI reduced from 34.4 to 8.3 events/hour at 6 months for 37 Singapore patients.","US limited market release (101 patients): no serious adverse events; 100% therapy usage at 60 days; average adherence 6.8 hrs/night.","AHI for first 34 US patients dropped from 30 to 4.5 events/hour; average stimulation amplitude 1.7V.","20% reduction in surgical times; average implant time 34.5 minutes at one site; new internal respiratory sensing eliminates pressure lead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139149,"accession_number":"0001609550-25-000040","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Systems CFO Rick Buchholz to step down by Dec 31, 2025; 2025 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Rick Buchholz resigns effective Dec 31, 2025, will remain in advisory role through Feb 28, 2026.","Transition agreement provides 9 months base salary and COBRA; departure not due to any dispute.","Company has begun search for new CFO with assistance of an executive search firm.","Reaffirms FY 2025 guidance: revenue $900-910M, gross margin 84-86%, diluted EPS $0.40-$0.50."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139148,"accession_number":"0001609550-25-000035","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inspire Medical Systems board authorizes $200M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $200M of common stock.","Program expires August 7, 2027, unless extended or terminated earlier.","CEO cites financial strength and confidence in growth as rationale.","Company states stock is undervalued and addressable market lightly penetrated.","Purchases may occur via open market or private transactions; no obligation to buy specific number."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139147,"accession_number":"0001609550-25-000030","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q2 net loss $3.6M, cuts FY 2025 revenue guidance to $900-910M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $217.1M (+11% YoY), net loss $3.6M vs prior year net income $9.8M.","Adjusted diluted EPS $0.45; GAAP diluted loss per share $0.12.","FY 2025 revenue guidance cut to $900-910M (prior $940-955M); EPS cut to $0.40-0.50 from $2.20-2.30.","Full U.S. launch of Inspire V neurostimulation system initiated.","EVP Randall Ban to retire on January 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":418403000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156689,"accession_number":"0001609550-25-000025","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inspire Medical Systems files investor presentation for June 2025 meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company will participate in investor and analyst meetings in June 2025.","Presentation materials furnished as Exhibit 99.1 but no specific content provided in filing.","No financial results, guidance, or material events disclosed in the 8-K body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156688,"accession_number":"0001609550-25-000019","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inspire Medical stockholders approve all proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class I director nominees elected: Burks (20.5M for), Herbert (21.1M for), McCormick (19.9M for).","Ratification of Ernst & Young as auditor for 2025: 28.4M for, 364K against, 8.4K abstain.","Advisory vote on executive compensation approved: 25.0M for, 1.86M against, 33K abstain (broker non-votes 1.82M).","Approximately 96.53% of outstanding shares (28.7M) represented at May 1, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156687,"accession_number":"0001609550-25-000018","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q1 rev $201.3M (+23% YoY), EPS $0.10; raises FY EPS guidance to $2.20-$2.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $201.3M, up 23% YoY; U.S. revenue $193.6M (+24%), OUS $7.7M (-6%).","Net income $3.0M (diluted EPS $0.10) vs net loss $10.0M ($0.34 loss) in Q1 2024.","Adjusted EBITDA $33.2M, up from $11.9M; operating loss improved 90% to $1.5M.","Surpassed 100,000 patients on Inspire therapy; Inspire V system launch starting in U.S. May 2025.","FY 2025 revenue guidance maintained $940-955M; EPS guidance raised to $2.20-$2.30 (from $2.10-$2.20)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":201317000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175100,"accession_number":"0001609550-25-000009","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q4 revenue $239.7M (+25% YoY); EPS $1.15; guides FY2025 rev $940-955M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $239.7M (+25% YoY); net income $35.2M, diluted EPS $1.15 vs $0.49 prior year.","Full year 2024 revenue $802.8M (+28% YoY); net income $53.5M ($1.75 diluted EPS) vs net loss in 2023.","FY2025 guidance: revenue $940-955M (17-19% growth); diluted EPS $2.10-$2.20.","Added 72 U.S. centers in Q4 (total 1,435); U.S. sales territories now 335; over 90,000 patients treated.","Initiated $75M accelerated share repurchase program; operating cash flow $130.2M for full year."],"consensus_eps_estimate":null,"consensus_eps_actual":1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":802804000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175099,"accession_number":"0001609550-25-000003","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical reports Q4 revenue ~$239.7M (+25% YoY); issues 2025 guidance $940-955M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue ~$239.5-239.7M, up 25% YoY; full year 2024 revenue ~$802.6-802.8M, up 28% YoY.","Initial FY2025 revenue guidance of $940-955M, representing 17-19% growth over FY2024.","Soft launch of Inspire V neurostimulator with over 40 implants completed in Singapore and U.S.","Appointed Jason Kelly as Chief Manufacturing and Quality Officer effective Jan 20, 2025; Dr. Sparks, CMO, left.","Activated 72 new U.S. centers in Q4 (total 1,435); 12 new sales territories (total 335)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":802804000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192048,"accession_number":"0001609550-24-000055","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Inspire Medical enters $75M accelerated share repurchase with Goldman Sachs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ASR agreement for $75M repurchase under existing $150M buyback program authorized by Board.","Payment of $75M on Nov 12; initial delivery of shares worth 80% of repurchase price based on Nov 8 close.","Final settlement in Q1 2025; Inspire may receive additional shares or pay cash to GS&Co. under terms.","ASR contains standard provisions for adjustments, early termination, and representations by both parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192047,"accession_number":"0001609550-24-000050","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q3 revenue $203.2M (+33% YoY), EPS $0.60 vs loss, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $203.2M, up 33% YoY; U.S. revenue $195.8M (+33%), OUS $7.4M (+27%).","Operating income $14.3M vs loss $13.5M; net income $18.5M, diluted EPS $0.60 vs loss $0.29.","Raises FY 2024 revenue guidance to $793-798M (27-28% growth) and EPS guidance to $1.20-1.40.","Activated 66 new U.S. centers (total 1,371); created 13 new sales territories (total 323).","Received FDA approval for Inspire V neurostimulation system; gross margin steady at 84.1%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":563086000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208533,"accession_number":"0001609550-24-000042","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Inspire Q2 revenue $195.9M (+30% YoY), EPS $0.32; raises FY guide, authorizes $150M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $195.9M (30% YoY), net income $9.8M vs loss $12.0M; diluted EPS $0.32 vs ($0.41).","FY 2024 revenue guidance raised to $788-798M (26-28% growth); EPS guidance raised to $0.60-0.80 from $0.10-0.20.","Board authorized $150M share repurchase program, first in company history, expiring August 5, 2026.","Received FDA approval for Inspire V neurostimulation system and EU MDR CE Mark for full-body MRI compatibility.","Activated 81 new U.S. centers in Q2 (total 1,316) and added 12 sales territories (total 310)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":359895000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208532,"accession_number":"0001609550-24-000036","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inspire Medical receives FDA approval for next-gen Inspire V neurostimulation system","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Inspire V system including next-generation neurostimulator, Bluetooth patient remote, and physician programmer.","Targets soft launch in late 2024 and full commercial launch in 2025.","Company focusing on operational readiness: product manufacturing and inventory levels for U.S. launch.","CEO cites FDA approval as a key milestone for Inspire therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208531,"accession_number":"0001609550-24-000034","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inspire Medical pre-announces Q2 revenue $195.9M (+30% YoY), raises 2024 guidance to $788-798M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $195.9M, up 30% YoY; US revenue $187.8M (+30%), OUS $8.1M (+27%).","Full-year 2024 revenue guidance raised to $788-798M, up $13M from prior $775-785M range.","Management cites strong execution and sequential US revenue growth acceleration.","Complete Q2 results and earnings call scheduled for August 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":359895000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208530,"accession_number":"0001609550-24-000032","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inspire Medical COO Philip Ebeling resigns effective Aug 9 to become CEO at private cardiology device firm","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philip J. Ebeling notified Inspire Medical on July 18, 2024 of his resignation as COO, effective Aug 9, 2024.","Ebeling leaves to become President and CEO of a private medical device company in the cardiology space.","Resignation was not due to any disagreement with the Company or its management.","Ebeling joined Inspire Medical in June 2020; the Company will conduct a search for a new COO with an executive search firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226230,"accession_number":"0001609550-24-000028","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inspire Medical shareholders elect directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class III director nominees elected: Broader (26.3M for), Dr. Curet (23.5M for), Tansey (26.1M for).","Ratification of Ernst & Young as independent auditor for FY2024 with 27.5M votes for, 833K against.","Advisory vote on named executive officer compensation approved with 25.9M for, 670K against.","28.3M shares represented, 95.44% of outstanding common stock; 1.57M broker non-votes on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226229,"accession_number":"0001609550-24-000024","cik":1609550,"company_name":"Inspire Medical Systems, Inc.","ticker":"INSP","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inspire Medical Q1 revenue $164M (+28% YoY); raises FY2024 guidance, expects full-year profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $164.0M, up 28% YoY; net loss narrowed to $10.0M ($0.34/share) from $15.4M.","U.S. revenue $155.8M (+25% YoY); OUS revenue $8.2M (+141%); gross margin 84.9% vs 84.4%.","FY2024 revenue guidance raised to $783-793M (25-27% growth); first-time diluted EPS guidance $0.10-$0.20.","Added 66 new U.S. centers (total 1,246) and 11 new sales territories (total 298) in Q1.","Ended Q1 with $469.2M cash; expects full-year 2024 profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":164010000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1252507767.4377072,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}